The introduction of imatinib just over ten years ago revolutionized chronic myeloid leukemia (CML) therapy, making long-term survival a reality for the majority of newly diagnosed patients. Unfortunately, residual disease remains detectable in most patients, and even patients with undetectable BCR --ABL (complete molecular response) have a substantial risk of disease recurrence upon discontinuation of imatinib. 1 Studies to understand the mechanism(s) underlying CML persistence in spite of ongoing, successful TKI-based disease management have mainly focused on cellintrinsic mechanisms. However, there is compelling evidence that the microenvironment has an important role in resistance to chemotherapy by providing critical survival cues to cells. 2 Therefore, we hypothesized that extrinsic factors may also contribute to CML disease persistence despite effective inhibition of BCR --ABL kinase activity by imatinib and second generation ABL inhibitors.
To investigate these extrinsic survival factors in a more physiologic context, we used immortalized human bone marrow stromal cells as a model of the microenvironment. 3 We found that conditioned media (CM) from HS-5, but not HS-23 or HS-27a, enhanced survival of CML cell lines in the presence of imatinib, dasatinib and nilotinib (Supplementary Figure 1) , consistent with previous reports.
4,5 Furthermore, we found that CML CD34 þ cells co-cultured with HS-5 cells, or cultured in transwells over HS-5 cells, also attenuated the effects of imatinib on colony formation (Supplementary Figure 1) . These data suggested that soluble factors may be responsible for HS-5-mediated protection from TKIs. We quantified the relative abundance of several cytokines in CM from the three human stromal cell lines to identify putative protective factors and found high concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), growth-related oncogene 1 (GRO1), monocyte chemotactic protein 1 (MCP-1), monocyte chemotactic protein 3 (MCP-3), granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) in HS-5 CM compared with HS-23 and HS-27a CM (data not shown). As several of these cytokines (G-CSF, GM-CSF, and IL-6) signal through JAK2, 6 we used CYT387, a JAK1/JAK2 inhibitor, and TG101209, a relatively specific JAK2 inhibitor, 7, 8 to interrogate the role of JAK2 in protection of CML cells by HS-5 CM.
We treated CML cell lines with 1 mM imatinib in RM or CM, combined with increasing concentrations of each JAK2 inhibitor and found that inclusion of 5 mM CYT387 or 1 mM TG101209 abolished the anti-apoptotic effect of CM (Figures 1a and b and Supplementary  Figure 2) , whereas JAK2 inhibitors alone induced little apoptosis. To determine whether JAK2 inhibition also abolished the protective effect of CM on primary cells, CML CD34 þ cells were co-cultured with HS-5 cells or in serum-free media for 4 days with the indicated concentrations of imatinib, CYT387 or both inhibitors, followed by clonogenic assays. Consistent with our results in K562 cells, HS-5 co-culture significantly increased CFU-GM formation in the presence of imatinib (23 ± 3.9% vs 9 ± 3.8%, P ¼ 0.018, Figure 1c) . Inclusion of CYT387 in addition to imatinib attenuated this difference in a dose-dependent manner (Figure 1c) . Similar results were obtained with the JAK2 inhibitor TG101209 (data not shown).
Study of downstream JAK2 signaling molecules identified phospho-STAT3 (pSTAT3) as a likely target of JAK2 (Supplementary Figures  3, 4) . Although we found that HS-5 CM increased phospho-STAT5 in LAMA-84, KBM-5 and CML progenitors, we found increased pSTAT3 in all CML cell lines and primary CD34 þ progenitors tested (Supplementary Figure 4) , suggesting a more broad role for STAT3, consistent with the data of others. 4 Of note, imatinib treatment increased pSTAT3 in all CML cell lines tested, and the amount of pSTAT3 was further enhanced in the presence of HS-5 CM, suggesting that inhibition of BCR --ABL induces a shift to an adaptive survival pathway that is substantially reinforced within the context of the microenvironment (Supplementary Figure 4) . This adaptive JAK2-STAT3 survival pathway can be attenuated by addition of the JAK2 inhibitors CYT387 and TG101209, which then restores sensitivity to ABL inhibitors (Figure 1) .
To test the effects of JAK2 and ABL inhibitors in vivo, we used a retroviral transduction/transplantation model of CML. 9, 10 Given that imatinib has limited efficacy in this model, these studies were performed with 75 mg/kg per day nilotinib, a more potent ABL inhibitor. 11 We used TG101209, because it is more selective for JAK2 compared with CYT387, at a maximum dose of 200 mg/kg per day based on previously published studies. 7 Mice were divided into five cohorts: vehicle control, TG101209 monotherapy (200 mg/kg per day), nilotinib monotherapy (75 mg/kg per day), and nilotinib (75 mg/kg per day) combined with either low-dose (50 mg/kg per day) or high-dose (200 mg/kg per day) TG101209.
Vehicle-treated mice died within two days of beginning treatment, demonstrating the aggressive nature of this CML model. 9, 10 Mice treated with TG101209 monotherapy demonstrated slightly prolonged survival (median survival of 20.5 days vs 15.5 days for the control, P ¼ 0.065), but eventually all mice succumbed to leukemia (Figures 2a --d) . The mice in the high-dose combination cohort initially fared well; however, two mice died unexpectedly on day 26 without any evidence of leukemia. As this data suggested toxicity, we terminated the remainder of the highdose combination cohort on day 27 for detailed autopsy. The nilotinib monotherapy and low-dose combination cohorts were continued on treatment until day 42. At this time, there were no significant differences in their peripheral blood counts or circulating GFP þ cells (data not shown), and the animals were killed for detailed analysis.
Autopsy of untreated and TG101209 monotherapy cohorts revealed diffuse leukemic infiltration of the spleen and liver (Figure 2d ). The nilotinib monotherapy and low-dose combination cohorts had smaller spleens (Figure 2b) , with restoration of normal splenic architecture (Figure 2d) . In contrast, the mice treated with the high-dose combination exhibited spleens that were nearly devoid of leukocytes and normal follicles (Figure 2d) . Similarly, mice treated with the high-dose combination had reduced bone marrow cellularity compared with the other cohorts (Figure 2d ). Mononuclear cells were isolated from all mice at time of death or sacrifice, and GFP þ cells from the spleen and bone marrow were measured by fluorescence-activated cell sorting to quantify residual disease. As shown in Figure 2e , there was a trend towards reduced splenic disease burden in the high-dose combination cohort when compared with nilotinib alone (4.1±4.1% GFP þ cells compared with 11.7±10.4% for nilotinib monotherapy, P ¼ 0.047). A less pronounced decrease of GFP þ cells was observed in the bone marrow (8.7±4.9% compared with 13.8±12% for nilotinib monotherapy, P ¼ 0.22).
JAK2 has long been implicated as an important signaling molecule in CML, although its exact role remains unclear. 12 --15 In our murine CML model, JAK2 inhibition alone only moderately prolonged survival, and all mice eventually succumbed to BCR --ABL þ myeloproliferative disease, suggesting that monotherapy merely delays disease progression. Combination treatment with nilotinib and high-dose TG101209 was more effective against BCR --ABL þ cells than nilotinib alone (Figure 2e ), but also suppressed normal hematopoietic cells, suggesting that any synergistic effect of JAK2 and ABL inhibition on BCR --ABL þ cells is nullified by toxic effects to non-leukemic cells at higher doses of JAK2 inhibitors (Figure 2 and similar results in non-leukemic control mice shown in Supplementary Figure 5 ). In contrast, combination treatments with a low-dose TG101209 component did not demonstrate any advantage over nilotinib alone (Figure 2) , suggesting a very narrow therapeutic window for combination JAK2 and ABL inhibitor therapy. More extensive drug combinations of imatinib, CYT387 and TG101209 in vitro with normal and CML CD34
þ cell colony formation also did not identify a combination that was able to preferentially suppress CML CD34 þ cell colony formation over normal CD34 þ cell colony formation (Supplementary Figure 6) . Considered together, these in vitro and in vivo results suggest that combinations of JAK2 and ABL inhibitors insufficiently discriminate between normal and CML cells to be of therapeutic use. As primary CD34 þ cells mainly reflect a progenitor population rather than true stem cells, it remains possible that a clinically relevant differential effect occurs in more primitive cells, although identifying the optimal pharmacokinetics and dosing will be challenging.
A number of other potential targets are currently being explored to eliminate CML disease persistence, including Wnt/ b-catenin, Hedgehog and FOXO3a. However, like JAK2, these molecules are also utilized by normal hematopoietic stem cells, raising the possibility that similar problems may be encountered when combination therapy is attempted in vivo. However, despite their many commonalities, CML cells expressing pharmacologically inactivated BCR --ABL are not identical to normal cells and it is conceivable that BCR --ABL inhibition may render a previously redundant survival pathway essential, thereby generating a new CML-specific vulnerability that spares normal cells. Identification of such a pathway would provide a rational target to eliminate CML stem cells and eradicate disease.
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